Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU

• Curium to get exclusive license to develop and commercialize PyL in EU and Progenics to get royalties on the net sales
•  The focus of the agreement is to advance the P-III CONDOR study and further commercialize it in the US
•  PyL is PSMA -targeted Positron Emission Topography (PET) used for visualizing bone & soft tissue metastases for determining metastatic prostate cancer. In Q1’ 19 Curium to get regulatory approval for PyL

Click here to read full press release/ article | Ref: Progenics | Image: Annualreports